Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly
- PMID: 31903478
- DOI: 10.1210/clinem/dgz317
Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly
Abstract
Context: Reports on the incidence, characteristics, and comorbidity in Asian patients with acromegaly are scarce.
Objective: To evaluate the incidence of acromegaly and the risk of comorbidities in East Asia, especially South Korea.
Design: This nationwide population-based cohort study using the Korean Health Insurance Review and Assessment claims database evaluated the incidence of acromegaly, initially diagnosed from 2010 to 2013. We identified comorbidities during, before, and 2 years after diagnosis. Acromegaly and control cases (718 and 7180, respectively) were included in the analysis.
Setting: A longitudinal case-control study using a nationwide population cohort.
Results: The mean annual incidence rate of acromegaly was 3.57 cases per 1 000 000. Malignancies occurred in 61 patients with acromegaly (8.5%) during the study period and thyroid cancer was the most common malignancy (n = 38). In the acromegaly group, the overall risk of malignancy was higher: hazard ratio (HR), 2.82 (95% confidence interval [CI]: 2.12-3.74). Malignancy risk was more pronounced in females, with increased risk from the prediagnosis period that is sustained until the postdiagnosis period. Prevalence of diabetes mellitus (DM) and heart failure increased significantly in acromegalic patients. Over the entire period, DM developed in 51.1% and 57.0% of male and female acromegalic patients, respectively. Mortality risk was higher (HR 1.65, 95%; CI: 1.13-2.41) and statistically significant in females (HR 1.75, 95%; CI: 1.07-2.84).
Conclusion: Comorbidities associated with acromegaly differed by sex in Korean subjects. High malignancy and mortality risk should be considered in female patients when managing acromegaly in Korea.
Keywords: acromegaly; comorbidity; diabetes mellitus; incidence; malignancy; mortality.
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Long-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data.Endocrinol Metab (Seoul). 2025 Feb;40(1):1-9. doi: 10.3803/EnM.2024.2285. Epub 2025 Feb 4. Endocrinol Metab (Seoul). 2025. PMID: 39901807 Free PMC article. Review.
-
Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea.J Korean Med Sci. 2021 Jun 14;36(23):e159. doi: 10.3346/jkms.2021.36.e159. J Korean Med Sci. 2021. PMID: 34128596 Free PMC article.
-
Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.Eur J Endocrinol. 2016 Sep;175(3):181-90. doi: 10.1530/EJE-16-0117. Epub 2016 Jun 8. Eur J Endocrinol. 2016. PMID: 27280374
-
Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea.Eur J Endocrinol. 2023 Aug 2;189(2):225-234. doi: 10.1093/ejendo/lvad106. Eur J Endocrinol. 2023. PMID: 37548222
-
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.Pituitary. 2016 Aug;19(4):448-57. doi: 10.1007/s11102-016-0725-2. Pituitary. 2016. PMID: 27279011 Free PMC article. Review.
Cited by
-
Effects of acromegaly treatment on left ventricular systolic function assessed by speckle tracking echocardiography in relation to sex differences: results from a prospective single center study.Front Endocrinol (Lausanne). 2023 May 8;14:1154615. doi: 10.3389/fendo.2023.1154615. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37223021 Free PMC article.
-
The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period.Clin Endocrinol (Oxf). 2022 Dec;97(6):773-782. doi: 10.1111/cen.14828. Epub 2022 Oct 6. Clin Endocrinol (Oxf). 2022. PMID: 36163677 Free PMC article.
-
Long-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data.Endocrinol Metab (Seoul). 2025 Feb;40(1):1-9. doi: 10.3803/EnM.2024.2285. Epub 2025 Feb 4. Endocrinol Metab (Seoul). 2025. PMID: 39901807 Free PMC article. Review.
-
Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea.J Korean Med Sci. 2021 Jun 14;36(23):e159. doi: 10.3346/jkms.2021.36.e159. J Korean Med Sci. 2021. PMID: 34128596 Free PMC article.
-
Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.J Endocrinol Invest. 2024 Jun;47(6):1457-1465. doi: 10.1007/s40618-023-02257-3. Epub 2024 Jan 12. J Endocrinol Invest. 2024. PMID: 38214852 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical